

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10510411
Filing Date	2005-09-12
First Named Inventor	Habib Zaghouni
Art Unit	1614
Examiner Name	To be assigned
Attorney Docket Number	07316.0002.PCUS00

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	6737057	B1	2004-05-18	Zaghouni	
	2	5969109		1999-10-19	Bona, et al.	
	3	5817308		1998-10-06	Scott, et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20030103967	A1	2003-06-05	Zaghouni	
	2	20020081298	A2	2002-06-27	Zaghouni	
	3	20020038002	A2	2002-03-28	Zaghouni	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10510411
Filing Date		2005-09-12
First Named Inventor	Habib Zaghouani	
Art Unit	1614	
Examiner Name	To be assigned	
Attorney Docket Number	07316.0002.PCUS00	

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0741788	EP	B1	2005-02-02	The American National Red Cross		<input type="checkbox"/>
	2	2004004642	WO	A2	2004-01-15	The University of Tennessee Research Corporation		<input type="checkbox"/>
	3	9830706	WO	A1	1998-07-16	Alliance Pharmaceutical Corporation		<input type="checkbox"/>
	4	9521926	WO	A1	1995-08-17	University of Rochester		<input type="checkbox"/>
	5	9009804	WO	A1	1990-09-07	The Regents of the University of California		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Balasa, B., et al., "A Mechanism for IL-10-Mediated Diabetes in the Nonobese Diabetic (NOD) Mouse: ICAM-1 Deficiency Blocks Accelerated Diabetes," The Journal of Immunology, Vol. 165, pp. 7330-7337 (2000)	<input type="checkbox"/>
	2	Bu, Ding-Fang, et al., "Two Human Glutamate Decarboxylases, 65-kDa GAD and 67-kDa GAD, Are Each Encoded by a Single Gene," Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 2115-2119 (1992)	<input type="checkbox"/>
	3	Gregg, Randal, et al., "IL-10 Diminishes CTLA-4 Expression on Islet-Resident T Cells and Sustains Their Activation Rather Than Tolerance," The Journal of Immunology, Vol. 174, pp. 662-670 (2005)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10510411
Filing Date		2005-09-12
First Named Inventor	Habib Zaghouni	
Art Unit	1614	
Examiner Name	To be assigned	
Attorney Docket Number	07316.0002.PCUS00	

4	Gregg, Randal, et al., "A Sudden Decline in Active Membrane-Bound TGF- β Impairs Both T Regulatory Cell Function and Protection Against Autoimmune Diabetes," The Journal of Immunology, Vol. 173, pp. 7308-7316 (2004)	<input type="checkbox"/>
5	Kaufman, D., et al., "Autoimmunity to Two Forms of Glutamate Decarboxylase in Insulin-Dependent Diabetes Mellitus," Journal of Clinical Investigation, Vol. 89, pp. 283-292 (1992)	<input type="checkbox"/>
6	Legge, K., et al., "Coupling of Peripheral Tolerance to Endogenous Interleukin 10 Promotes Effective Modulation of Myelin-Activated T Cells and Ameliorates Experimental Allergic Encephalomyelitis," J. Exp. Med., Vol. 191, No. 12, pp. 2039-2051 (2000)	<input type="checkbox"/>
7	Legge, K., et al., "Multi-Modal Antigen Specific Therapy for Autoimmunity," Intern. Rev. Immunol., Vol. 20, pp. 593-611 (2001)	<input type="checkbox"/>
8	Zambidis, E., et al., "Epitope-Specific Tolerance Induction with An Engineered Immunoglobulin," Proc. Natl. Acad. Sci. USA, Immunology, Vol. 93, pp. 5019-5024 (1996)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10510411
Filing Date	2005-09-12
First Named Inventor	Habib Zaghouani
Art Unit	1614
Examiner Name	To be assigned
Attorney Docket Number	07316.0002.PCUS00

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).


OR

- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☒ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature		Date (YYYY-MM-DD)	2006-11-21
Name/Print	David B. Fournier, Esq.	Registration Number	51,696

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**